<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668562</url>
  </required_header>
  <id_info>
    <org_study_id>20150656</org_study_id>
    <nct_id>NCT02668562</nct_id>
  </id_info>
  <brief_title>Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor</brief_title>
  <acronym>RAPID CABG</acronym>
  <official_title>Reassessment of Anti-Platelet Therapy Using InDividualized Strategies -Ticagrelor in Patients With Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery - A Pharmacodynamic and Clinical Study to Decrease Bleeding Risks and Ischemic Complications - The RAPID-TITRATE CABG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ticagrelor, a more potent P2Y12 inhibitor, has been shown to reduce major adverse cardiac
      events (MACE) in acute coronary syndromes (ACS). It is increasingly used as a first line
      therapy in ACS. However, more potent P2Y12 inhibition has been associated with increased
      bleeding. This may be of particular concern for patients with ACS who require coronary artery
      bypass surgery (CABG). In particular, the timing for cessation of ticagrelor before
      proceeding to CABG is unclear. RAPID TITRATE CABG is a randomized vanguard study to evaluate
      the feasibility and preliminary safety of a strategy of early versus delayed CABG in ACS
      patients initially treated with ticagrelor and to identify potential mechanisms underlying
      benefits or complications of early bypass surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe-massive bleeding</measure>
    <time_frame>24 hours post CABG</time_frame>
    <description>Class 3 or 4 UDPB (universal definition for peri-operative bleeding)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other major bleeding criteria (BARC)</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) CABG-related (Type 4) bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other major bleeding criteria (TIMI)</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>TIMI major/minor CABG bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other major bleeding criteria (CABG related life threatening bleed)</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>CABG-related life-threatening bleed including: cardiac tamponade, all intracranial bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion (RBC)</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>Red Blood Cell (RBC) transfusion (in Units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion (Platelet)</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>Platelet transfusion (in Units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative biomarker rise</measure>
    <time_frame>48 hours post CABG</time_frame>
    <description>CK, troponin rise post CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Major Adverse Cardiovascular Events (MACE) (To be collected but blinded to investigators,as this data will be carried from the vanguard study into a future definitive clinical trial).</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>MACE defined as composite of cardiovascular death, recurrent myocardial infarction, stroke, refractory ischemia, or urgent unplanned revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Individual Components of Major Adverse Cardiovascular Events (MACE) (To be collected but blinded to investigators,as this data will be carried from the vanguard study into a future definitive clinical trial).</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>cardiovascular death, recurrent myocardial infarction, stroke, refractory ischemia, or urgent unplanned revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 Reactivity Units (PRU) as a continuous variable</measure>
    <time_frame>Baseline (at CABG), 24, 48, 72 hours post CABG</time_frame>
    <description>Platelet Function as Measured by VerifyNow P2Y12 assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADP-induced Aggregation (AU) as a continuous variable</measure>
    <time_frame>Baseline (at CABG), 24, 48, 72 hours post CABG</time_frame>
    <description>Platelet Function as Measured by Multiplate analyzer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Early CABG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to undergo early CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients to undergo delayed CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early CABG (Day 2-3 after ticagrelor discontinuation)</intervention_name>
    <description>Timing for CABG after ticagrelor discontinuation</description>
    <arm_group_label>Early CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Delayed CABG (Day 5-7 after ticagrelor discontinuation)</intervention_name>
    <description>Timing for CABG after ticagrelor discontinuation</description>
    <arm_group_label>Delayed CABG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACS patient referred for CABG and have received &gt;= 1 dose of ticagrelor before
             decision for CABG made

        Exclusion Criteria:

        Patients are excluded if they:

          -  refuse consent for enrollment

          -  are deemed to require immediate CABG (Day 0 or day 1)

          -  have a ST-elevation myocardial infarction (STEMI )initially treated with primary PCI

          -  are undergoing concurrent valve surgery

          -  are intolerant or allergic to aspirin

          -  have been on an oral anticoagulant (including a vitamin K antagonist or a NOAC)

          -  received adjuvant therapy with a glycoprotein IIbIIIa inhibitor

          -  have a co-morbidity with life-expectancy of &lt; 1 year

          -  have active bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek So, MD FRCPC FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Derek So, MD FRCPC FACC</last_name>
    <phone>613-761-5387</phone>
    <email>DSo@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lyne Stuewe, BScN</last_name>
    <phone>613-761-4646</phone>
    <email>LStuewe@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyne Stuewe, BScN</last_name>
      <phone>613-761-4646</phone>
      <email>lstuewe@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Derek So, MD FRCPC FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Gabor-Popa</last_name>
      <email>George.Gabor-Popa@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Tanguay, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>coronary artery bypass surgery</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>platelet function testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

